Henoch-Schönlein purpura (HSP), the most common type of leukocytoclastic vasculitis, is caused by T cell-mediated autoimmune reactions. In this study, we analyze histone modification patterns in peripheral blood mononuclear cells (PBMCs) of HSP patients, and investigate the expression levels of inflammatory cytokines (IFN-γ, IL-2, IL-4, IL-6 and IL-13), transcription factors (T-bet, GATA-3 and TIM-1) and chemokines (CXCL4 and CXCL10) in HSP patients. Our results show that histone H3 acetylation and methylation are significantly enhanced in PBMCs from HSP patients. We also demonstrate specifically that marked increases in histone H3 acetylation and H3 lysine 4 trimethylation occur at the IL-4 loci in these patients. In addition, the expression levels of IL-4, IL-6, IL-13, GATA-3, TIM-1 and CXCL4 are also increased. These findings suggest that abnormal histone modifications are present in the PBMCs of patients with HSP, possibly contributing to the activation of pathological immune responses associated with HSP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2012.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive Laboratory Markers for Gastrointestinal Complications in Children with Henoch-Schönlein Purpura.
J Multidiscip Healthc
January 2025
Department of Rheumatology and Immunology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &Technology, Wuhan, 430016, People's Republic of China.
Background: Henoch-Schönlein Purpura (HSP) is a common systemic vasculitis in children that often involves the gastrointestinal system (GIS). Identifying reliable predictive markers for GIS complications is crucial for early intervention and improved patient outcomes.
Objective: This study aims to identify laboratory markers predictive of GIS complications in children with HSP using a machine learning approach.
The Impact of Infectious Diseases on Clinical Characteristics and Immunological Correlations in Pediatric Henoch-Schönlein Purpura: A Five-Year Retrospective Study.
Biomedicines
January 2025
Discipline of Clinical Laboratory and Food Safety, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania.
Immunoglobulin A (IgA) vasculitis (IgAV), classically known as Henoch-Schönlein purpura (HSP), is a type of nonthrombocytopenic small-vessel vasculitis. HSP is the most frequent kind of systemic vasculitis in children, characterized by purpura, arthritis or arthralgia, gastrointestinal pain, and kidney dysfunction. The aim of our research was to investigate and observe the clinical characteristics of children diagnosed with HSP and to explore the correlation between infectious diseases and HSP.
View Article and Find Full Text PDFComparison of low-level laser therapy versus neuromuscular electrical nerve stimulation at hemiplegic shoulder pain and upper extremity functions.
Lasers Med Sci
January 2025
Department of Physical Medicine and Rehabilitation, Hitit University Erol Olçok Education and Research Hospital, Çorum, Turkey.
This study aimed to assess and compare the effectiveness of adding low-level laser therapy (LLLT) and neuromuscular electrical nerve stimulation (NMES) to conventional physical therapy exercises, for stroke patients with hemiplegic shoulder pain (HSP). Seventy-five stroke patients with shoulder pain were included in this prospective randomized controlled study. Participants were divided into three groups.
View Article and Find Full Text PDFDelphi Consensus on the Management of Spanish Patients with Post-Stroke Hemiplegic Shoulder Pain Treated with Botulinum Toxin A: Result Study.
Toxins (Basel)
January 2025
Doctor Negrín University Hospital of Gran Canaria, Pl. Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain.
The study aimed to identify expert opinions and obtain recommendations on the management of post-stroke hemiplegic shoulder pain (HSP) and treatment with botulinum toxin A (BoNT-A). A multicenter Delphi study was conducted using an online survey designed by a committee of experts with at least 10 years of experience in post-stroke HSP management with BoNT-A in Spain. Forty-seven panelists (specialists with at least 5 years of experience in post-stroke HSP management with BoNT-A) rated their level of agreement in two rounds based on acceptance by ≥66.
View Article and Find Full Text PDFHSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
Blood
January 2025
Hospital Santa Creu i Sant Pau, Barcelona, Spain.
CD30-directed CART cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the non-soluble part of CD30, and the manufacturing process includes a modulation of ex vivo T cell activation, as well as the addition of interleukin-21 to IL-7 and IL-15 to promote stemness of T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!